Marengo Therapeutics

CompanyUnited States

Marengo Therapeutics develops one asset, in phase 2 (Invikafusp alfa in tumor mutational burden-high solid tumors). Mostly protein or enzyme; based in the United States.

1
Asset
Furthest stage
Phase 2
2
Trials
0
Signals

Pipeline

1
  • Invikafusp alfa

    Activates selected T cells through T-cell receptor binding and interleukin-2 signaling.

    Phase 2, Protein or enzyme, tumor mutational burden-high solid tumors, bladder cancer

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials2
  • Similar companies6

Intelligence